Keywords: Roche, Herceptin, USA, FDA, Stomach cancer, Biogen Idec, Ocrelizumab

US FDA approves Genentech/Roche’s Herceptin for HER2-positive metastatic stomach cancer; Roche amends deal with Biogen

Article | 22 October 2010

Print This

US biotech giant Genentech, part of Swiss drug major Roche (ROG: VX), says the US Food and Drug Administration has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in